Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06221176 · ClinicalTrials.gov registry record · NA
Biomarkers Research in Anxiety for Validation and Efficacy
A NA study of Autism Spectrum Disorder and Autism, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06221176: Recruiting NA study of Autism Spectrum Disorder and Autism, sponsored by Boston Children's Hospital.
NCT06221176 is a NA study of Autism Spectrum Disorder and Autism that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 25 participants, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06221176, a NA study of Autism Spectrum Disorder and Autism, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
A within-subjects design will be used for this preliminary investigation of four biomarkers across two contexts of use: prediction of treatment response (i.e., stratification) and quantification of response (i.e., change).
Primary Outcome
Parents of children ages 3 to 5 will complete the SPAS and parents of 6 year old children will complete the SCAS. These are questionnaires designed to assess the severity of anxiety symptoms in preschool-aged and school-aged children. Scores range from 0-136 with higher scores indicating greater anxiety.
Conditions Studied
Interventions
- BEHAVIORAL Being Brave
Study Locations (1)
Massachusetts
- Boston Children's Hospital, Two Brookline Place - Brookline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-04-02 |
| Est. Completion | 2025-08-01 |
| Phase | NA |
What NCT06221176 shows while recruiting
NCT06221176 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (81% lower).
The record links to 2 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 1 intervention - of which Being Brave is the first listed.
NCT06221176 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06221176 about?
NCT06221176 is a clinical study titled "Biomarkers Research in Anxiety for Validation and Efficacy". A within-subjects design will be used for this preliminary investigation of four biomarkers across two contexts of use: prediction of treatment response (i.e., stratification) and quantification of response (i.e., change).
What is the current status of trial NCT06221176?
This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2024-04-02. Estimated completion is 2025-08-01.
What conditions does trial NCT06221176 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Autism.
What interventions are being tested in trial NCT06221176?
The interventions under investigation include: Being Brave (BEHAVIORAL).
Who is sponsoring clinical trial NCT06221176?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06221176 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06221176's enrollment target sits among peer trials
25 183rd of 224 higher than 38 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Emergent Multi-Class Imitation Training
RECRUITING · NA
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
RECRUITING · NA
-
Cerebellum and Autism: Regional Specialization for Social and Executive Functions
RECRUITING · NA
-
Milieu Teaching-AV (MT-AV Pilot)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI